Literature DB >> 28004202

The impact of early versus late levodopa administration.

Gilad Yahalom1,2, Oren S Cohen3,4, Naama Warmann-Alaluf3, Chen Shabat3, Hanna Strauss3, Sandra Elincx-Benizri3, Simon Israeli-Korn3, Esther Stein3, Lior Greenbaum3, Sharon Hassin-Baer3,4.   

Abstract

Long-term levodopa therapy in patients with Parkinson's disease (PD) is associated with motor complications including motor fluctuations (MF) and levodopa-induced dyskinesias (LID). The time to appearance of MF and LID is apparently related to both the timing and the duration of levodopa therapy, but is highly variable. We performed a retrospective analysis of all levodopa-treated PD patients to explore the effect of time from PD onset to levodopa initiation on time to MF or LID. We used a Cox multivariate regression model after stratifying patients into four quartiles, according to the time to levodopa initiation. Data from 170 PD patients (117 males, age at onset: 65.1 ± 11.6 years, time to levodopa treatment: 23.8 ± 28.4 months) was included in the analysis. Early levodopa administration was associated with a shorter time from diagnosis to both MF (p < 0.001) and LID (p = 0.001). The hazard ratio to develop MF and LID from the time of PD diagnosis was 2.48 (p < 0.001) and 2.71 (p = 0.002), respectively. In our population, we found that delaying levodopa administration was associated with a longer time to the appearance of motor complications after diagnosis. While disease duration is the most important determinant of the onset of motor complications, delaying levodopa could prolong the 'complication-free' period.

Entities:  

Keywords:  Delaying motor complications; Early levodopa administration; Late levodopa administration; Levodopa sparing

Mesh:

Substances:

Year:  2016        PMID: 28004202     DOI: 10.1007/s00702-016-1669-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  16 in total

1.  Risk factors for levodopa-induced dyskinesias in Parkinson's disease.

Authors:  F Grandas; M L Galiano; C Tabernero
Journal:  J Neurol       Date:  1999-12       Impact factor: 4.849

2.  Levodopa and the progression of Parkinson's disease.

Authors:  Stanley Fahn; David Oakes; Ira Shoulson; Karl Kieburtz; Alice Rudolph; Anthony Lang; C Warren Olanow; Caroline Tanner; Kenneth Marek
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

Authors:  U K Rinne; F Bracco; C Chouza; E Dupont; O Gershanik; J F Marti Masso; J L Montastruc; C D Marsden
Journal:  Drugs       Date:  1998       Impact factor: 9.546

4.  Experimental treatment of parkinsonism with L-Dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  Neurology       Date:  1968-03       Impact factor: 9.910

Review 5.  Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.

Authors:  M Horstink; E Tolosa; U Bonuccelli; G Deuschl; A Friedman; P Kanovsky; J P Larsen; A Lees; W Oertel; W Poewe; O Rascol; C Sampaio
Journal:  Eur J Neurol       Date:  2006-11       Impact factor: 6.089

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

8.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Authors:  R Katzenschlager; J Head; A Schrag; Y Ben-Shlomo; A Evans; A J Lees
Journal:  Neurology       Date:  2008-06-25       Impact factor: 9.910

9.  Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

Authors:  Richard Gray; Natalie Ives; Caroline Rick; Smitaa Patel; Alastair Gray; Crispin Jenkinson; Emma McIntosh; Keith Wheatley; Adrian Williams; Carl E Clarke
Journal:  Lancet       Date:  2014-06-11       Impact factor: 79.321

10.  The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.

Authors:  Roberto Cilia; Albert Akpalu; Fred Stephen Sarfo; Momodou Cham; Marianna Amboni; Emanuele Cereda; Margherita Fabbri; Patrick Adjei; John Akassi; Alba Bonetti; Gianni Pezzoli
Journal:  Brain       Date:  2014-07-17       Impact factor: 13.501

View more
  3 in total

1.  Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?

Authors:  Seok Jong Chung; Han Soo Yoo; Hye Sun Lee; Hyo Eun Jeong; Soo-Jong Kim; Jungsu S Oh; Jae Seung Kim; Young H Sohn; Phil Hyu Lee
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

2.  Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.

Authors:  Han Soo Yoo; Seok Jong Chung; Su Jin Chung; Hyojeong Moon; Jung Su Oh; Jae Seung Kim; Jin Yong Hong; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-26       Impact factor: 9.236

Review 3.  Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.

Authors:  Luxi Wang; Nian Xiong; Jinsha Huang; Shiyi Guo; Ling Liu; Chao Han; Guoxin Zhang; Haiyang Jiang; Kai Ma; Yun Xia; Xiaoyun Xu; Jie Li; Jing Y Liu; Tao Wang
Journal:  Front Aging Neurosci       Date:  2017-06-28       Impact factor: 5.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.